Cyber extortion group FulcrumSec claims to have stolen over 1TB of sensitive data from Novo Nordisk, including source code, drug information, and clinical trial data. The group allegedly demanded $25 million, which Novo Nordisk reportedly refused to pay. FulcrumSec is now reportedly exploring selling the stolen data.
Die Hackergruppe FulcrumSec fordert 25 Millionen Dollar Lösegeld vom Pharmakonzern Novo Nordisk, nachdem sie über ein Terabyte an Daten erbeutet hat. Das Unternehmen lehnte die Zahlung ab. Die Hacker drohen nun mit der Veröffentlichung oder dem Verkauf der gestohlenen Daten, darunter sensible Informationen zu Medikamenten und KI-Modellen.
Die Hackergruppe FulcrumSec fordert 25 Millionen Dollar Lösegeld vom Pharmakonzern Novo Nordisk, nachdem sie über ein Terabyte an Daten erbeutet hat. Das Unternehmen verweigert die Zahlung, und die Hacker drohen mit der Veröffentlichung oder dem Verkauf der gestohlenen Informationen, darunter sensible Medikamentendaten und KI-Modelle.
Die Erpressergruppe FulcrumSec behauptet, Novo Nordisk habe eine Lösegeldzahlung von 25 Mio. USD verweigert, nachdem sie über ein Terabyte an Daten gestohlen hatten. Die Hacker drohen nun mit dem Verkauf der Daten, ziehen aber eine kostenlose Veröffentlichung vor, um andere Unternehmen abzuschrecken.
Cyberkriminelle der Gruppe FulcrumSec behaupten, über ein Terabyte an Daten von Novo Nordisk gestohlen zu haben, darunter Quellcodes und vertrauliche Medikamenteninformationen. Das Unternehmen bestätigte einen IT-Sicherheitsvorfall und verweigert eine Lösegeldzahlung von 25 Millionen Dollar.
Grupo hacker FulcrumSec alega ter roubado mais de 700 mil arquivos da Novo Nordisk, incluindo dados de pacientes e funcionários, e ameaça vender as informações após não conseguir extorquir US$ 25 milhões da empresa.
A EMS lançou sua caneta de semaglutida, Ozivy, nas farmácias brasileiras. O medicamento, primeiro nacional após a queda da patente, tem preço inicial de R$ 452 e visa controlar o nível de açúcar no sangue.
Drugmakers are exploring new obesity treatments beyond GLP-1s, including less frequent shots and pills with fewer side effects. Eli Lilly's experimental drug retatrutide showed significant weight loss, while competitors like Novo Nordisk, Structure Therapeutics, AstraZeneca, Pfizer, and Amgen are developing new oral and injectable options. The market is expected to grow significantly, with pricing and insurance coverage being key factors.
A pill version of the weight-loss drug Wegovy has been approved in the UK by the MHRA. Manufacturer Novo Nordisk states the once-daily tablet offers convenience over weekly injections and doesn't require refrigeration. Its availability on the NHS is pending expert assessment.
The UK has approved a pill version of the weight-loss drug Wegovy, manufactured by Novo Nordisk. This once-daily tablet, containing semaglutide, mimics a natural hormone to suppress appetite and slow digestion. While available via prescription from pharmacies soon, its NHS availability is pending expert assessment.
Novo Nordisk has launched its weight loss pill Wegovy in the United Arab Emirates, marking its first expansion outside the US. The drug, approved for weight management and cardiovascular risk reduction, faces increasing competition in the growing obesity drug market.
Novo Nordisk has launched its weight loss pill Wegovy in the United Arab Emirates, marking its first expansion outside the U.S. market. The drug's approval by the Emirates Drug Establishment follows recent competition from Eli Lilly in the growing obesity drug sector.
Medicamento para obesidade, semaglutida, chega ao Brasil com preço acessível. Versão nacional da EMS custará R$ 287 por mês na fase inicial, bem abaixo dos R$ 1 mil mensais anteriores.
The European Medicines Agency has recommended Novo Nordisk's Wegovy pill for adults with obesity or overweight conditions, potentially making it Europe's first oral weight-loss drug. Approved in the US in December 2025, the daily tablet offers an alternative to injectable versions.
Novo Nordisk plans a major global push for its Wegovy weight-loss pill, aiming to expand beyond the U.S. market. The company's EVP, Emil Kongshøj Larsen, stated they will go "all in" on launches pending approvals, citing potential in patient interest and telehealth partnerships. This comes as Novo faces increasing competition from Eli Lilly's rival pill, Foundayo.
Hims & Hers' stock fell 13% after reporting a Q1 net loss of $92M, weak earnings guidance, and ongoing controversy over weight loss drug sales, despite a deal with Novo Nordisk.
Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.
Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.
Hims & Hers shares fell 15.5% in premarket trading after the company reported a $92 million first-quarter loss and provided earnings guidance that disappointed investors.
Hims & Hers shares fell in premarket trading after the company reported a $92 million first-quarter net loss and issued guidance that Citi described as mixed. Investors also focused on the firm's transition away from compounded GLP-1 sales.
New generics in Canada likely mark the start of a decline in international revenue of semaglutide, the active ingredient in Novo's Ozempic and Wegovy.
Novo Nordisk CEO Mike Doustdar says the Ozempic and Wegovy maker is looking for deals more than ever before.
Novo Nordisk raised its outlook for 2026 after a strong performance from its newly launched Wegovy pill.
Novo Nordisk raised its outlook for 2026 after a strong performance from its newly launched Wegovy pill.
